Greenfield Videos

1. Addressing The PAT Developability Gap 10/1/2025

   In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists discuss how organizations can develop a PAT continuum or program that aligns development teams and manufacturing teams in PAT adoption and use.

2. Taking An Institutional Approach To PAT Implementation 10/1/2025

   In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists emphasize the importance of strategic planning for PAT implementation and the value of cross-training. Mengyao Li, Ph.D., from Novartis suggests taking a stage-gated approach and starting with the “low-hanging fruit.”

3. What Are The Biggest Barriers To PAT Adoption? 10/1/2025

   In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists discuss technology adoption and explain how risk aversion can impact PATs moving forward as a process matures.

4. Using PATs For Real-Time Process Monitoring 10/1/2025

   In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists respond to results from an audience poll. Audience members indicated they use PATs for real-time process monitoring more in upstream than in downstream. 

5. How CMC And MSAT Teams Consider PATs 10/1/2025

   In this segment from the Bioprocess Online Live event, “Aligning CMC And MSAT To Move PATs Out Of Pilot Mode,” our panelists emphasize the importance of strategic planning for PAT implementation and the value of cross-training. Mengyao Li, Ph.D., from Novartis suggests taking a stage-gated approach and starting with the “low-hanging fruit.”

6. Aligning CMC And MSAT To Move PATs Out Of Pilot Mode 9/9/2025

   In this on-demand event, CMC and MSAT experts Yanhuai (Richard) Ding, Ph.D., senior director of CMC at EvolveImmune Therapeutics; Thomas Kowski, VP of analytical development at Umoja Biopharma; Mengyao Li, Ph.D., principal scientist at Novartis; and Luc Nguyen, Ph.D., head of MSAT for vaccines at Sanofi, discuss how companies can align their teams to overcome internal barriers and unlock the promise of PATs.